News about Clinical Trials

TG Therapeutics Launches Phase 2 Trial of BRIUMVI for Schizophrenia

TG Therapeutics has initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia, evaluating B-cell depletion as a potential therapy for patients with immune dysfunction.

Clinical Trials | 07/07/2026 | By News Bureau

Opus Genetics Aligns with US FDA on Phase 3 OPGx-LCA5 Trial

Opus Genetics has aligned with the US Food and Drug Administration (FDA) on the Phase 3 trial design for OPGx-LCA5 in inherited retinal disease, with phase 3 dosing expected in Q4 2026 and a potential Biologics License Application (BLA) submission based on 6-month efficacy data.

Clinical Trials | 07/07/2026 | By News Bureau

AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression

AtaiBeckley has completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01 for treatment-resistant depression. The company expects topline results in the fourth quarter of 2026 and plans to expand the therapy into major depressive disorder and generalized anxiety disorder, subject to positive clinical outcomes.

Clinical Trials | 07/07/2026 | By News Bureau

Ionis Completes Enrollment in Phase 3 REVEAL Study for Angelman Syndrome

Ionis has completed enrollment in the pivotal Phase 3 REVEAL study of obudanersen for Angelman syndrome, with topline clinical trial results expected in the second half of 2027.

Clinical Trials | 06/07/2026 | By Akanki |  131

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of Japanese Cedar Allergy Vaccine

Immunomic Therapeutics has initiated Phase 1 clinical testing of ITI-9001 after dosing the first participant in Japan, advancing the development of a next-generation therapeutic vaccine for Japanese cedar pollen allergy.

Clinical Trials | 06/07/2026 | By News Bureau

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib

Revolution Medicines presented phase 1/2 clinical data showing the potential of zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer at ESMO Gastrointestinal Cancers Congress 2026.

Clinical Trials | 04/07/2026 | By News Bureau

Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer

Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.

Clinical Trials | 04/07/2026 | By News Bureau

Otsuka's Voyxact Phase 3 Trial Shows Long-Term Kidney Protection in IgA Nephropathy

Otsuka's Voyxact delivered significant long-term kidney function stabilization and reduced the risk of kidney failure in the Phase 3 VISIONARY trial, strengthening its potential as a disease-modifying treatment for IgA nephropathy.

Clinical Trials | 04/07/2026 | By News Bureau |  182

Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial

Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior progression-free and overall survival over approved first-generation therapies in the Phase III Krascendo 1 trial, marking a significant advance in the treatment of previously treated KRAS G12C-mutated non-small cell lung cancer.

Clinical Trials | 04/07/2026 | By News Bureau |  139

Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Roche’s divarasib demonstrated superior Progression-Free Survival over approved KRAS G12C inhibitors in the phase 3 Krascendo-1 trial for previously treated advanced Non-Small Cell Lung Cancer (NSCLC).

Clinical Trials | 02/07/2026 | By News Bureau